Protocol Ledger

NCT06062069 · Phase II · COMPLETED

A Study of CT-868 in Type 1 Diabetes Mellitus

Interventional Phase II clinical trial protocol NCT06062069 sponsored by Roche / Genentech in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-27 Enrollment: 111 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06062069
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)111 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06062069
Protocol FieldVerified Registry Value
NCT IdentifierNCT06062069
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment111 participants (ACTUAL)
Registered Start Date2023-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06062069
Hospital Research SiteLocationSite Profile
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->
University of North Carolina at Chapel HillChapel Hill, NCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI